Bone health study of a long-acting factor VIII for hemophilia A
Part of Blood & lymphatic clinical trials.
This study tests whether a long-acting factor VIII medicine (rFVIIIFc) helps protect the bones and joints of people with hemophilia A. If you have severe or moderate hemophilia with joint damage and are already on this treatment, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe hemophilia A, or moderate hemophilia A with joint damage from bleeds
- You are currently taking a long-acting factor VIII drug (rFVIIIFc) to prevent bleeds
- You have been on a regular (standard) factor VIII treatment for at least one year in the past
- You are willing to have tests on your bones and joints (like X-rays or scans)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a new factor VIII medicine, efanesoctocog alfa, protects your joints over time. It's for people with moderate or severe hemophilia A who are just starting this treatment.
This study compares two preventive treatments for severe hemophilia A—emicizumab versus factor VIII—to see how they affect joint and bone health. It may help you and others understand which option better protects joints and bones over the next several years.
This study compares how two different hemophilia A treatments affect bone strength and health in men over time. Researchers will track bone density and collect blood samples to understand whether one treatment protects bones better than the other.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
This trial tests a new long-acting factor VIII treatment (FRSW107) for people with severe hemophilia A. It aims to prevent bleeding episodes with fewer injections, and you must have already used factor VIII treatments many times before.
Hear when a new Severe Hemophilia A Without Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.